Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets

Leonardo Mirandola, Jose A. Figueroa, Tam T. Phan, Fabio Grizzi, Minji Kim, Rakhshanda Layeequr Rahman, Marjorie R. Jenkins, Everardo Cobos, Cynthia Jumper, Raed Alalawi, Maurizio Chiriva-Internati

Research output: Contribution to journalArticlepeer-review

Abstract

Lung cancer is the leading cause of cancer deaths in both genders worldwide, with an incidence only second to prostate cancer in men and breast cancer in women. The lethality of the disease highlights the urgent need for innovative therapeutic options. Immunotherapy can afford efficient and specific targeting of tumor cells, improving efficacy and reducing the side effects of current therapies. We have previously reported the aberrant expression of cancer/testis antigens (CTAs) in tumors of unrelated histological origin. In this study we investigated the expression and immunogenicity of the CTAs, Sperm Protein 17 (SP17), A-kinase anchor protein 4 (AKAP4) and Pituitary Tumor Transforming Gene 1 (PTTG1) in human non-small cell lung cancer (NSCLC) cell lines and primary tumors. We found that SP17, AKAP4 and PTTG1 are aberrantly expressed in cancer samples, compared to normal lung cell lines and tissues. We established the immunogenicity of these CTAs by measuring CTA-specific autoantibodies in patients' sera and generating CTA-specific autologous cytotoxic lymphocytes from patients' peripheral blood mononuclear cells. Our results provide proof of principle that the CTAs SP17/AKAP4/PTTG1 are expressed in both human NSCLC cell lines and primary tumors and can elicit an immunogenic response in lung cancer patients.

Original languageEnglish
Pages (from-to)2812-2826
Number of pages15
JournalOncotarget
Volume6
Issue number5
Publication statusPublished - 2015

Keywords

  • Cancer vaccines
  • Cancer/testis antigens
  • Lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets'. Together they form a unique fingerprint.

Cite this